A Case Report of Pemphigus Vulgaris Initially Misdiagnosed as Tinea Capitis: Infectious Consequences of Diagnostic Delay in a Patient Treated With Rituximab.

Publication date: Jul 01, 2025

Pemphigus vulgaris is a rare and potentially life-threatening autoimmune blistering disorder affecting the skin and mucous membranes. Prompt diagnosis and appropriate treatment are crucial in preventing severe complications. We report the case of a 53-year-old woman with severe pemphigus vulgaris who was misdiagnosed as having tinea capitis for approximately four months. During this time, she received multiple courses of systemic antifungals and antibiotics without clinical improvement, resulting in the progressive dissemination of lesions, including mucosal and ocular involvement. The correct diagnosis was ultimately established through skin biopsy, and immunosuppressive therapy with prednisone and rituximab was initiated. During immunosuppression, the patient developed severe infections due to Pseudomonas aeruginosa, extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli, and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), necessitating the temporary suspension of rituximab and the introduction of intravenous immunoglobulin as a bridging strategy. The patient experienced favorable clinical evolution, with more than 80% reepithelialization and the resolution of infectious complications. This case underscores the importance of considering autoimmune diseases in treatment-refractory scalp dermatoses, avoiding prolonged empirical antimicrobial use, and employing a multidisciplinary approach in immunosuppressed patients at high risk of infection.

Open Access PDF

Concepts Keywords
Biopsy delayed diagnosis
Coronavirus intravenous immunoglobulin
Immunosuppressive pemphigus vulgaris
Months rituximab
Woman tinea capitis

Semantics

Type Source Name
disease MESH Pemphigus Vulgaris
disease MESH Tinea Capitis
drug DRUGBANK Rituximab
disease MESH complications
drug DRUGBANK Prednisone
disease IDO immunosuppression
disease MESH infections
drug DRUGBANK Immune Globulin Human
disease MESH autoimmune diseases
disease MESH scalp dermatoses
disease IDO infection
pathway REACTOME Reproduction
drug DRUGBANK Coenzyme M
disease MESH Allergy
disease MESH acantholysis
disease MESH patchy alopecia
disease MESH bacteremia
disease MESH urinary tract infection
disease IDO history
disease MESH hypertension
disease MESH diabetes mellitus
disease MESH hypothyroidism
disease MESH alopecia
disease MESH superinfection
drug DRUGBANK Miconazole
drug DRUGBANK Fusidic Acid
drug DRUGBANK Itraconazole
drug DRUGBANK Cephalexin
drug DRUGBANK Doxycycline
disease MESH bullae
drug DRUGBANK Gold
disease MESH inflammation
disease MESH rheumatoid arthritis
pathway KEGG Rheumatoid arthritis
disease MESH bloodstream infection
drug DRUGBANK Ceftazidime
drug DRUGBANK Amikacin
disease MESH clinical course
disease MESH COVID 19
disease MESH dermatoses
disease MESH misdiagnosis
disease MESH bacterial infection
disease MESH impetigo
disease MESH folliculitis
disease MESH actinomycosis
disease MESH discoid lupus erythematosus
disease MESH lichen planopilaris
disease MESH cicatricial pemphigoid
disease MESH scarring
disease MESH cutaneous T cell lymphoma
disease MESH metastases
disease MESH conjunctivitis
disease MESH keratitis
disease MESH viral infection
disease MESH dysbiosis
disease MESH recurrent infections
disease MESH Pneumocystis jirovecii pneumonia
disease MESH infectious diseases
disease IDO symptom
drug DRUGBANK Bismuth subgallate
disease MESH relapse
disease MESH ulcers
disease MESH pemphigoid
drug DRUGBANK Cefradine
drug DRUGBANK Amber
drug DRUGBANK Azathioprine
drug DRUGBANK Mycophenolate mofetil

Original Article

(Visited 4 times, 1 visits today)